Cargando…
Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment
Diabetes mellitus (DM) is a risk factor for hepatocellular carcinoma (HCC). The purpose of this study was to investigate the impact of the disorder of glucose metabolism on the recurrence of HCC after curative treatment. Two hundred and eleven patients with HCC who received curative treatment in our...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387449/ https://www.ncbi.nlm.nih.gov/pubmed/30704150 http://dx.doi.org/10.3390/ijms20030605 |
_version_ | 1783397584587456512 |
---|---|
author | Imai, Kenji Takai, Koji Hanai, Tatsunori Suetsugu, Atsushi Shiraki, Makoto Shimizu, Masahito |
author_facet | Imai, Kenji Takai, Koji Hanai, Tatsunori Suetsugu, Atsushi Shiraki, Makoto Shimizu, Masahito |
author_sort | Imai, Kenji |
collection | PubMed |
description | Diabetes mellitus (DM) is a risk factor for hepatocellular carcinoma (HCC). The purpose of this study was to investigate the impact of the disorder of glucose metabolism on the recurrence of HCC after curative treatment. Two hundred and eleven patients with HCC who received curative treatment in our hospital from 2006 to 2017 were enrolled in this study. Recurrence-free survival was estimated using the Kaplan–Meier method, and the differences between the groups partitioned by the presence or absence of DM and the values of hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), fasting immunoreactive insulin (FIRI), and homeostasis model assessment-insulin resistance (HOMA-IR) were evaluated using the log-rank test. There were no significant differences in the recurrence-free survival rate between the patients with and without DM (p = 0.144), higher and lower levels of HbA1c (≥6.5 and <6.5%, respectively; p = 0.509), FPG (≥126 and <126 mg/dL, respectively; p = 0.143), and FIRI (≥10 and <10 μU/mL, respectively; p = 0.248). However, the higher HOMA-IR group (≥2.3) had HCC recurrence significantly earlier than the lower HOMA-IR group (<2.3, p = 0.013). Moreover, there was a significant difference between the higher and lower HOMA-IR groups without DM (p = 0.009), and there was no significant difference between those groups with DM (p = 0.759). A higher HOMA-IR level, particularly in non-diabetic patients, was a significant predictor for HCC recurrence after curative treatment. |
format | Online Article Text |
id | pubmed-6387449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-63874492019-02-27 Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment Imai, Kenji Takai, Koji Hanai, Tatsunori Suetsugu, Atsushi Shiraki, Makoto Shimizu, Masahito Int J Mol Sci Article Diabetes mellitus (DM) is a risk factor for hepatocellular carcinoma (HCC). The purpose of this study was to investigate the impact of the disorder of glucose metabolism on the recurrence of HCC after curative treatment. Two hundred and eleven patients with HCC who received curative treatment in our hospital from 2006 to 2017 were enrolled in this study. Recurrence-free survival was estimated using the Kaplan–Meier method, and the differences between the groups partitioned by the presence or absence of DM and the values of hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), fasting immunoreactive insulin (FIRI), and homeostasis model assessment-insulin resistance (HOMA-IR) were evaluated using the log-rank test. There were no significant differences in the recurrence-free survival rate between the patients with and without DM (p = 0.144), higher and lower levels of HbA1c (≥6.5 and <6.5%, respectively; p = 0.509), FPG (≥126 and <126 mg/dL, respectively; p = 0.143), and FIRI (≥10 and <10 μU/mL, respectively; p = 0.248). However, the higher HOMA-IR group (≥2.3) had HCC recurrence significantly earlier than the lower HOMA-IR group (<2.3, p = 0.013). Moreover, there was a significant difference between the higher and lower HOMA-IR groups without DM (p = 0.009), and there was no significant difference between those groups with DM (p = 0.759). A higher HOMA-IR level, particularly in non-diabetic patients, was a significant predictor for HCC recurrence after curative treatment. MDPI 2019-01-30 /pmc/articles/PMC6387449/ /pubmed/30704150 http://dx.doi.org/10.3390/ijms20030605 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Imai, Kenji Takai, Koji Hanai, Tatsunori Suetsugu, Atsushi Shiraki, Makoto Shimizu, Masahito Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment |
title | Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment |
title_full | Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment |
title_fullStr | Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment |
title_full_unstemmed | Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment |
title_short | Homeostatic Model Assessment of Insulin Resistance for Predicting the Recurrence of Hepatocellular Carcinoma after Curative Treatment |
title_sort | homeostatic model assessment of insulin resistance for predicting the recurrence of hepatocellular carcinoma after curative treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387449/ https://www.ncbi.nlm.nih.gov/pubmed/30704150 http://dx.doi.org/10.3390/ijms20030605 |
work_keys_str_mv | AT imaikenji homeostaticmodelassessmentofinsulinresistanceforpredictingtherecurrenceofhepatocellularcarcinomaaftercurativetreatment AT takaikoji homeostaticmodelassessmentofinsulinresistanceforpredictingtherecurrenceofhepatocellularcarcinomaaftercurativetreatment AT hanaitatsunori homeostaticmodelassessmentofinsulinresistanceforpredictingtherecurrenceofhepatocellularcarcinomaaftercurativetreatment AT suetsuguatsushi homeostaticmodelassessmentofinsulinresistanceforpredictingtherecurrenceofhepatocellularcarcinomaaftercurativetreatment AT shirakimakoto homeostaticmodelassessmentofinsulinresistanceforpredictingtherecurrenceofhepatocellularcarcinomaaftercurativetreatment AT shimizumasahito homeostaticmodelassessmentofinsulinresistanceforpredictingtherecurrenceofhepatocellularcarcinomaaftercurativetreatment |